Jaguar Health reports completion of preclinical studies of lechlemer
Jaguar Health announced the completion of the two short-term preclinical toxicology studies in rats and dogs intended to support continued development of lechlemer, the human drug product candidate of Jaguar's wholly-owned subsidiary, Napo Pharmaceuticals, for the symptomatic relief of diarrhea from cholera and potentially other acute infectious diarrheal conditions. The completion of these initial studies support the initiation of longer term toxicity and safety pharmacology studies that the company expects will support the Investigational New Drug application Jaguar plans to file for lechlemer. As previously announced, Napo received preclinical services supported by the National Institute of Allergy and Infectious Diseases to support development of lechlemer. NIAID is part of the National Institutes of Health. Under NIAID's suite of preclinical services, NIAID-funded contractors conducted the initial 7-day rat and dog toxicology studies.